Advances in methods for therapeutic peptide discovery, design and development

Current Pharmaceutical Biotechnology

Volumn 12, Issue 8, 2011, Pages 1117-1127

  Pirogova, E ^a   Istivan, T ^a   Gan, E ^a   Cosic, I ^a  

^a RMIT UNIVERSITY   (Australia)

Author keywords

Cancer therapeutics; Digital signal processing; Drug discovery; Frequency; Peptide de novo design; Protein function

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CGP 38560; DNA TOPOISOMERASE (ATP HYDROLYSING); G PROTEIN COUPLED RECEPTOR; I KAPPA B; INTERLEUKIN 12; INTERLEUKIN 2; LACTATE DEHYDROGENASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PROLYL ENDOPEPTIDASE; PROTEIN P53; RAS PROTEIN; SMALL INTERFERING RNA; STROMELYSIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BIOINFORMATICS; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CANCER THERAPY; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELL CYCLE ARREST; CELL DEATH; CELL INVASION; CELL PROLIFERATION; COMBINATORIAL CHEMISTRY; COMPUTER MODEL; CRYSTAL STRUCTURE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFECT; DRUG METABOLISM; DRUG TOXICITY; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE DELETION; GENETIC ALGORITHM; GENOMICS; HIGH THROUGHPUT SCREENING; HLA SYSTEM; HUMAN; HYBRIDIZATION; HYDROPHILICITY; HYDROPHOBICITY; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CLEARANCE; METASTASIS; MODEL; MOLECULAR RECOGNITION; MOLECULAR WEIGHT; MORBIDITY; MORTALITY; NONHUMAN; ONCOGENE C MYC; PARKINSON DISEASE; PHARMACOKINETICS; PHARMACOLOGY; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEOMICS; RESONANT RECOGNITION MODEL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR SUPPRESSOR GENE; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; L-LACTATE DEHYDROGENASE; MICROSCOPY, CONFOCAL; MOLECULAR SEQUENCE DATA; NEOPLASMS; PEPTIDES;

EID: 79959941671     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111796117436     Document Type: Article

References (76)

1. Bidwell, G.L. III; Raucher, D. Therapeutic peptides for cancertherapy. Part I - peptide inhibitors of signal transduction cascades. Expert Opin. Drug Deliv., 2009, 6(10), 1033-1047.
2. Dolle, R.E. Comprehensive survey of chemical libraries yieldingenzyme inhibitors, receptor agonists and antagonists, and other biologicallyactive agents: 1992 through 1997. Mol. Diversity, 1998, 3,199-233.
3. Pickett, S.D.; McLay, I.M.; Clark, D.E. Enhancing the hit-to-leadproperties of lead optimization libraries. J. Chem. Inf. Comput. Sci.,2000, 40, 263-272.
4. Belda, I.; Llorma, X.; Martinell, M.; Tarrago, T.; Giralt, E. Computer-aided peptide evolution for virtual drug design, illigal reportno. 2004015, illinois genetic algorithms laboratory university of illinoisat urbana-Champaign, 2004.
5. Zeng, J. Mini-review: Computational structure-based design ofinhibitors that target proteins surfaces. Comb. Chem. HighThroughput Screen, 2000, 3, 355-362.
6. Fogel, G.B.; Corne, D.W. Evolutionary Computation in Bioinformatics, Elsevier Science, 2002.
7. Teixido, M.; Belda, I.; Rosello, X.; Gonzalez, S.; Fabre, M.; Llorma, X.; Bacardit, J.; Garrell, J.M.; Vilaro, S.; Albericio, F.; Giralt, E. Development of a genetic algorithm todesign and identifypeptides that can cross the blood-brain barrier. QSAR Comb. Sci.,2003, 22 (7), 745-753.
8. Patel, S.; Stott, I.; Bhakoo, M.; Elliott, P. Patenting evolved bactericidalpeptides. In creative evolutionary systems, Morgan KaufmannPublishers, 2001, 525-545.
9. Kamphausen, S.; Hltgen, N.; Wirsching, F.; Morys-Wortmann, C.; Riester, D.; Goetz, R.; Thrk, M.; Schwienhorst, A. Genetic algorithmfor the design of molecules with desired properties. J. Computer-Aided Mol. Des., 2002, 16, 551-567.
10. Budin, N.; Majeux, N.; Tenette, C.; Caflisch, A. Structure-basedligand design by a build-up approach and genetic algorithm searchin conformational space. J. Computat. Chem., 2001, 22(16), 1956-1970.
11. Colas, P.; Cohen, B.; Jessen, T. Genetic selection of peptide aptamersthat recognize and inhibit cyclin-dependent kinase 2. Nature,1996, 380(6574), 548-550.
12. Colas, P. Combinatorial protein reagents to manipulate proteinfunction, Curr. Opin. Chem. Biol., 2000, 4(1):54-59.
13. Borghouts, C.; Kunz, C.; Groner, B. Peptide aptamers: recent developmentsfor cancer therapy", Expert Opin. Biol. Ther., 2005,5(6), 783-797.
14. Porath, J.; Flodin, P. Gel filtration: a method for desalting andgroup separation. Nature, 1959, 183, 1657-1659.
15. Peterson, E.A.; Sober, H.A. Chromatography of proteins. I. Celluloseion-exchange adsorbents. J. Am. Chem. Soc., 1956, 78, 751-755.
16. Craig, L.C.; King, T.P. Design and use of a 1000-tube countercurrentdistribution apparatus. Fed. Proc., 1958, 17, 1126-1134.
17. Sewald, N.; Jakubke, H.-D. Peptides: Chemistry and Biology. Wiley-VCH Verlag GmbH & Co., 2002.
18. Ripka, A.S.; Rich, D.H. Peptidomimetic design. Curr. Opin.Chem.Biol., 1998, 2, 441-452.
19. Petsalaki, E.; Stark, A.; Garcia-Urdiales, E.; Russell, R.B. AccuratePrediction of Peptide Binding Sites on Protein Surfaces. Plos. Computat. Biol., 2009, 5.
20. Frenkel, D.; Clark, D.E.; Li, J.; Murray, C.W.; Robson, B. Pro-Ligand - an Approach to De-Novo Molecular Design.4. Applicationto the Design of Peptides. J. Comput.-Aided Mol. Des., 1995,9, 213-225.
21. Hetenyi, C.; Van der Spoel, D. Efficient docking of peptides toproteins without prior knowledge of the binding site. Protein Sci.,2002, 11, 1729-1737.
22. Juretic, D.; Vukicevic, D.; Ilic, N.; Antcheva, N.; Tossi, A. ComputationalDesign of Highly Selective Antimicrobial Peptides. J.Chem. Inform. Model., 2009, 49, 2873-2882.
23. Mayrose, I.; Penn, O.; Erez, E.; Rubinstein, N.D.; Shlomi, T. Pepitope:epitope mapping from affinity-selected peptides. Bioinformatics,2007, 23, 3244-3246.
24. Moreau, V.; Fleury, C.; Piquer, D.; Nguyen, C.; Novali, N. PEPOP:Computational design of immunogenic peptides. BMC Bioinformatics,2008, 9.
25. Stein, A.; Aloy, P. A molecular interpretation of genetic interactionsin yeast. FEBs. Lett., 2008, 582, 1245-1250.
26. Unal, E.B., Gursoy, A.; Erman, B. VitAL: Viterbi Algorithm for denovo Peptide Design. PLoS One, 2010, Vol. 5, Issue 6.
27. Ajay, A.; Walters, W.P.; Murcko, M.A. Can we learn to distinguishbetween "drug-like" and "nondrug-like" molecules? J. Med.Chem., 1998, 41, 3314-3324.
28. Abe, K.; Kobayashi, N.; Sode, K.; Ikebukuro, K. Peptide ligandscreening of asynuclein aggregation modulators by in silico panning. BMC Bioinformatics, 2007, 8, 451.
29. Kamphausen, S.; Holtge, N.; Wirsching, F.; Morys-Wortmann, C.; Riester, D. et al. Genetic algorithm for the design of moleculeswith desired properties. J. Comput. Aided Mol. Des., 2002, 16,551-567.
30. Riester, D.; Wirsching, F.; Salinas, G.; Keller, M.; Gebinoga, M. Thrombin inhibitors identified by computer-assisted multiparameterdesign. Proc. Nat. Acad. Sci. USA, 2005, 102, 8597-8602.
31. Klepeis, J.L.; Floudas, C.A.; Morikis, D.; Tsokos, C.G.; Lambris, J.D. Design of peptide analogues with improves activity using anovel de novo protein design approach. Industrial & EngineeringChemistry Research, 2004, 43, 3817-3826.
32. Singh, J.; Ator, M.A.; Jaeger, E.P.; Allen, M.P.; Whipple, D.A. Application of genetic algorithms to combinatorial synthesis: Acomputational approach to lead identification and lead optimization. J. Am. Chem. Soc., 1996, 118, 1669-1676.
33. Budin, N.; Ahmed, S.; Majeux, N.; Caflisch, A. An evolutionaryapproach for structure-based design of natural and nonnatural peptidicligands. Comb. Chem. High Throughput Screen, 2001, 4, 661-673.
34. Budin, N.; Majeux, N.; Caflisch, A. Fragment-based flexible liganddocking by evolutionary optimization. Biological Chemistry, 2001,382, 1365-1372.
35. Budin, N.; Majeux, N.; Tenette-Souaille, C.; Caflisch, A. Structurebasedligand design by a build-up approach and genetic algorithmsearch in conformational space. Journal of Computational Chemistry,2001, 22, 1956-1970.
36. Bright, R.K.; Franz, R.W. Book Reveiw. Peptide-based cancervaccines. Leukemia, 2002, 16, 970-971, DOI: 10.1038/sj/leu/2402436.
37. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell. 2000,100, 57-70.
38. Hahn, W.C.; Weinberg, R.A. Rules for making human tumor cells. N. Engl. J. Med., 2002, 347, 1593-1603.
39. Feinberg, A.P. The epigenetics of cancer etiology. Semin. CancerBiol., 2004, 14, 427-432.
40. Futreal, P.A.; Coin, L.; Marshall, M.; Down, T.; Hubbard, T.; Wooster, R.; Rahman, N.; Stratton, M.R. A census of human cancergenes. Nat. Rev. Cancer, 2004, 4, 177-183.
41. Borghouts, C.; Kunz, C.; Groner, B. Current strategies for the developmentof peptide-based anti-cancer therapeutics. J. PeptideSci., 2005, 11, 713-726 DOI: 10.1002/psc.717.
42. Weinstein, I.B. "Cancer addiction to oncogenes-the Achilles healof cancer", Science, 2002, 297, 63-64.
43. Waldmann, T.A. Immunotherapy: past, present and future. Nat.Med., 2003, 9, 269-277. doi:10.1038/nm0303-269.
44. Old, L.J. Immunotherapy for cancer. Sci. Am., 1996, 275, 136-143.
45. Knutson, K.L.; Schiffman, K.; Disis, M.L. Immunization with aHER-2/neu helper peptide vaccine generates HER-2/neu CD8 Tcell immunity in cancer patients. J. Clin. Invest., 2001, 107, 477-484.
46. McCarty, M.F. Targeting multiple signaling pathways as a strategyfor managing prostate cancer: multifocal signal modulation therapy.Integr. Cancer Ther., 2004, 3, 349-380.
47. Buerger, C.; Nagel-Wolfrum, K.; Kunz, C.; Wittig, I.; Butz, K.; Hoppe-Seyler, F.; Groner, B. Sequence-specific peptide aptamers,interacting with the intracellular domain of the epidermal growthfactor receptor, interfere with Stat3 activation and inhibit thegrowth of tumor cells. J. Biol. Chem., 2003, 278, 37610-37621.
48. Kardinal, C.; Konkol, B.; Lin, H.; Eulitz, M.; Schmidt, E.K.; Estrov, Z.; Talpaz, M.; Arlinghaus, R.B.; Feller, S.M. Chronic myelogenousleukemia blast cell proliferation is inhibited by peptidesthat disrupt Grb2-SoS complexes. Blood, 2001, 98, 1773-1781.
49. Mai, J.C.; Mi, Z.; Kim, S.H.; Ng, B.; Robbins, P.D. A proapoptoticpeptide for the treatment of solid tumor. Cancer Res., 2001, 61,7709-7712.
50. Mendoza, F.J.; Espino, P.S.; Cann, K.L.; Bristow, N.; McCrea, K.; Los, M. Anti-tumor chemotherapy utilizing peptide-based approaches-apoptotic pathways, kinases, and proteasome as targets, Arch. Immunol. Ther. Exp. (Warsz), 2005, 53, 47-60.
51. Nagel-Wolfrum, K.; Buerger, C.; Wittig, I.; Butz, K.; Hoppe-Seyler, F.; Groner, B. The interaction of specific peptide aptamerswith the DNA binding domain and the dimerization domain of thetranscription factor Stat3 inhibits transactivation and induces apoptosisin tumor cells. Mol. Cancer Res., 2004, 2, 170-182.
52. Wang, H.L.; Kurtz, A. Breast cancer growth inhibition by deliveryof the MDGI-derived peptide P108". Oncogene, 2000, 19, 2455-2460.
53. Zhang, J.; Spring, H.; Schwab, M. Neuroblastoma tumor cellbindingpeptides identified through random peptide phage display. Cancer Lett., 2001, 171, 153-164.
54. Lev, D.C.; Kim, L.S.; Melnikova, V.; Ruiz, M.; Ananthaswamy, H.N.; Price, J.E. Dual blockade of EGFR and ERK1/2 phosphorylationpotentiates growth inhibition of breast cancer cells. Br. J.Cancer, 2004, 91, 795-802.
55. McCarty, M.F. Targeting multiple signaling pathways as a strategyfor managing prostate cancer: multifocal signal modulation therapy.Integr. Cancer Ther., 2004, 3, 349-380.
56. Tortora, G.; Caputo, R.; Damiano, V.; Melisi, D.; Bianco, R.; Fontanini, G.; Veneziani, B. M; De Placido, S.; Bianco, A.R.; Ciardiello, F. Combination of a selective cyclooxygenase-2 inhibitor withepidermal growth factor receptor tyrosine kinase inhibitor ZD1839and protein kinase A antisense causes cooperative antitumor andantiangiogenic effect. Clin. Cancer Res., 2003, 9, 1566-1572.
57. Talmadge, J.E. Pharmacodynamic aspects of peptide administrationbiological response modifiers. Adv. Drug Deliv. Rev., 1998, 33(3),241-52
58. Lipka, E.; Crison, J.; Amidon, G.L. Transmembrane transport ofpeptide type compounds: prospects for oral delivery. J. Control Release.1996, 39(2-3), 121-129.
59. Park, Y.J.; Chang, L.C.; Liang, J.F.; Moon, C.; Chung, C.P.; Yang, V.C. Nontoxic membrane translocation peptide from protamine,low molecular weight protamine (LMWP), for enhanced intracellularprotein delivery: in vitro and in vivo study. FASEB J., 2005, 19,1555-1557.
60. Schmidt, M.M.; Wittrup, K.D. A modeling analysis of the effectsof molecular size and binding affinity on tumor targeting. Mol.Cancer Ther., 2009, 8, 2861-2871.
61. Truhlar, D.G.; Howe, D.G.; Hopfinger, A.J.; Blaney, J.; Dammokoehler, R.E. (Eds). Rational Drug Design. Springer, 1999.
62. Cosic, I. Macromolecular bioactivity: Is it Resonant Interactionbetween Molecules? - Theory and Applications. IEEE Trans. BME.1994, 41, 1101-1114.
63. Cosic, I. The Resonant Recognition Model of MacromolecularBioactivity: Theory and Applications. Birkhauser Verlag., 1997.
64. Cosic, I. Spectroscopy for fun and profit. Nat. BioTech., 1995, 13,236-238.
65. Cosic, I.; Hodder, A.N.; Aguilar, M.I.; Hearn, M.T.W. ResonantRecognition Model and Protein Topography: Model Studies withMyoglobin, Hemoglobin and Lysozyme. Eur. J. Biochem., 1991,198, 113-119.
66. Veljkovic, V.; Slavic, M. General model of pseudopotentials. Phy.Rev. Lett., 1972, 29, 105-108.
67. Cosic, I.; Drummond, A.E.; Underwood, J.R.; Hearn, M.T.W. Invitro inhibition of the actions of basic FGF by a novel 16 amino cidpeptide. Mol. Cell. Biochem., 1994, 130, 1-9.
68. Krsmanovic, V.; Biquard, J.M.; Sikorska-Walker, M.; Cosic, I., Desgranges, C.; Trabaud, M.A.; Whitfield, J.F.; Durkin, J.P.; Achour, A.; Hearn, M.T.W. Investigation into the cross-reactivityof rabbit antibodies raised against nonhomologous pairs of syntheticpeptides derived from HIV-1 gp120 proteins. J. Peptide Res.,1998, 52(5), 410-4120.
69. Gately, M.K.; Wolitzy, A.G.; Quinn, P.M.; Chizzonite, R. Regulationof human cytolytic lymphocyte responses by interleukin-12.Cell. Immunol., 1992, 143:127.
70. Robertson, M.; Ritz, J. Interleukin 12: Basic biology and potentialapplications in cancer treatment. Oncologists, 1996, 1, 88-97.
71. Brunda, M.J; Luistro, L. Antitumor and antimetastatic activity ofInterleukin 12 against murine tumors. J. Exp. Med., 1993, 178,1223-1230.
72. Kozar, K.; Kaminski, R. Interleukin 12-based immunotherapyimproves the antitumor effectiveness of a low-dose 5-aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanomamodels in mice. Clin. Cancer Res., 2003, 9, 3124-3133.
73. Den Otter, W.; Jacobs, J.J.L. Local therapy of cancer with free IL-2. Cancer Immunol. Immunother., 2008, 57(7), 931-950.
74. Klebanoff, C.A.; Finkelstein, S.E.; Surman, D.R. IL-15 enhancesthe in vivo antitumor activity of tumor-reactive CD8- T Cells. Proc.Natt. Acad Sci. USA, 2004, 101(7), 1969-1974.
75. Takaki, R.; Hayakawa, Y. IL-21 Enhances Tumor Rejectionthrough a NKG2D-Dependent Mechanism1. J. Immunol., 2005,175, 2167-2173.
76. Borden, E.C.; Sondel, P.M. Lymphokines and cytokines as cancertreatment Immunotherapy realized. Cancer, 1990, 65(3 Suppl),800-814.